Restarting Medications After Upper Gastrointestinal Bleeding (UGIB) Stabilization

Antiplatelet Therapy

The American College of Cardiology recommends restarting aspirin as soon as hemostasis is achieved if used for secondary cardiovascular prevention, with strong recommendation and moderate quality evidence 1, 2
Patients who discontinued aspirin had a 10-fold higher mortality and nearly 7-fold increased risk of death or acute cardiovascular events, highlighting the importance of early resumption 3
The American Heart Association suggests restarting P2Y12 inhibitor therapy within 5 days maximum after hemostasis, with strong recommendation and moderate quality evidence 1, 2
Dual antiplatelet therapy should never be stopped simultaneously in patients with coronary stents, and management should be done in liaison with cardiology, with strong recommendation and moderate quality evidence 1

The American College of Chest Physicians recommends interrupting warfarin at presentation and restarting at 7 days after hemorrhage in patients with low thrombotic risk, with strong recommendation and low quality evidence 1, 5
For patients with high thrombotic risk, bridging with low molecular weight heparin should be considered at 48 hours after hemostasis, with strong recommendation and low quality evidence 1, 5
Direct oral anticoagulants should be interrupted at presentation and restarted at maximum 7 days after hemorrhage, with weak recommendation and very low quality evidence 1, 4

The optimal timing of resuming anticoagulation therapy balances the competing risks of rebleeding and thrombotic complications, with most rebleeds occurring within the first 5 days and delayed resumption increasing thrombotic complications and mortality 2, 3

Platelet transfusions should never be given routinely to patients on antiplatelet agents with GI bleeding, as it does not reduce rebleeding but is associated with higher mortality, according to the American Society of Hematology 3
Mortality from GI bleeding is generally related to comorbidity and thrombotic complications, not exsanguination, highlighting the importance of careful management, with evidence from the European Society of Gastrointestinal Endoscopy 5